Health·NIST

Seven Gut Microbiome Tests, One Sample of Poop

A NIST study found home gut microbiome tests can give conflicting answers from the same sample. The problem may lie in the tests themselves.

  • NIST sent one identical stool sample to seven companies; for 17 of 18 shared genera, testing noise matched or exceeded real person-to-person variation.
  • One company’s three identical kits returned conflicting verdicts: two “healthy,” one “unhealthy” flagging seven of ten categories, all passing internal quality checks.
  • Companies disagreed on basics: only three genera appeared in every sample, and three of seven flagged C. difficile while four did not.

One sample. One donor. One gut microbiome testing company. Three identical kits, mailed off and then waited on for two to eight weeks. Two reports came back clean. The third declared the gut unhealthy, flagged seven of ten functional categories as below average, and gently nudged the customer to do something about it. And no one at the company noticed: the dodgy report sailed through their own quality checks and posted to the account like any other.

That sample never came from a real customer. It came from a freezer at the National Institute of Standards and Technology, where a team of microbiologists had been buying up at-home gut microbiome kits to see what these tests actually deliver.

The premise is by now familiar from the advertising. Spit in a tube and learn about your ancestry; deposit something rather less pleasant on a swab and learn, supposedly, about the bustling ecosystem in your gut and what to eat to improve it. The microbes down there, the bacteria and fungi and viruses lining your gastrointestinal tract, really do seem tangled up with everything from mood to obesity to how well some cancer treatments work. So the appetite for a peek inside is understandable. The question NIST set out to answer was narrower and more awkward: if you send the very same gut to seven different companies, do you get the same gut back?

You do not. Not even close.

Putting the Tests to the Test

To run a fair trial you need samples that are identical, and this is where NIST had an unusual advantage. The institute produces and sells standard reference fecal material, painstakingly homogenised and characterised, the kind of thing used to anchor research into fecal transplants (which are exactly what they sound like, and which can help treat conditions like colitis and may even nudge cancer patients toward better responses to treatment). Leftover donor material from that effort was perfect for the job. The researchers ordered three kits each from seven companies, twenty-one in all, created accounts under personal email addresses so nobody knew they were being watched, and inoculated every kit from the same homogenised pool.

“A team of microbiologists at NIST recently put these tests … well … to the test using precisely measured stool samples we already had in our labs,” writes Stephanie Servetas, the microbiologist who led the work.

The reports came back weeks later, and they disagreed with each other as much as if they’d come from eight different people. The team split one identical sample among several companies, then ran eight separate donors through a single workflow. The noise from the testing process was as large as the real biological differences. For 17 of 18 common microbial genera, the variation from the testing matched or exceeded the variation between actual people. Only one genus, Haemophilus, held steady. In plain terms: the lab is shouting louder than the gut.

Why so much scatter? Because turning a smear of stool into a tidy pie chart is a long chain of fiddly steps, and bias can creep in at every link. Some companies asked customers to sample a whole bowel movement, others to swipe used toilet paper. Some had you drop the swab in a buffer, some wanted it shipped back neat. None packed any ice, so everything travelled at whatever temperature the postal service happened to provide. Then come the choices invisible to the customer: how the DNA is pulled out, which stretch of bacterial gene is read, how deeply, and which software decides what’s what. More sequencing did not even guarantee more answers. One firm reported over 600 species per sample on a shallow read; another, reading roughly five hundred times deeper, found fewer than a hundred.

Even the headline question of who is living in your gut went unsettled. Across all nine analyses, only three genera showed up in every single sample. And the test for Clostridioides difficile, a nasty pathogen you’d want flagged accurately, split the room: three of the seven companies said it was present, four said it wasn’t. Same sample.

What This Means If You Spit, Swab and Hope

None of which, Servetas is careful to say, amounts to a verdict of fraud or quackery. “This variability in results doesn’t mean I would advise people not to take these tests. In fact, I may try one myself one day,” she writes, adding that she’d quite like to test her whole family someday and compare notes (that’s a microbiologist’s idea of fun, apparently). The trouble is mostly that the science is young, barely twenty years old, and there’s still no agreed picture of what a “normal” microbiome even looks like. Many of the companies recommend dietary tweaks, which seems harmless enough. Some go further and sell their own probiotic supplements, the clinical evidence for which is thin.

The people most likely to buy these kits, it’s worth remembering, are often those wrestling with chronic gut problems and running out of options. For them a wobbly result isn’t a curiosity; it’s a possible wrong turn, or a delay before they see someone who can actually help. “I generally know how microbes interact with the body but not necessarily how the body responds to microbes,” Servetas writes, deferring, as she suggests the rest of us should, to a doctor.

So the advice is unglamorous but sound: read your report with a healthy dose of skepticism, and don’t overhaul your life on the strength of it without talking to someone who knows your medical history. The longer game, though, is more hopeful. Having finished the study, NIST went back to the companies, most of whom were game to keep working together, and the institute is now collaborating with the field to tighten up the measurements. The dream is to drag these tests closer to the boring reliability of a blood panel, where a result means roughly the same thing whoever runs it.

“Our ultimate goal is to help these tests become more like a blood test, so they can potentially be part of your regular health screenings,” Servetas writes. Until that day arrives, your gut, it seems, will keep telling slightly different stories depending on who you ask.

  • Study type: Analytical-performance / interlaboratory reproducibility evaluation using a standardized reference material (a benchmarking study, not a clinical or human-outcomes trial); peer-reviewed, published in Communications Biology(2026)
  • Subject of evaluation: Seven commercial direct-to-consumer (DTC) gut microbiome testing services, each sent aliquots of a single homogenized NIST human fecal reference material; companies were blinded to the assessment until after all reports were returned
  • Comparator: Within-company replicates vs. across-company results; separately, methodological variability (one sample, different companies) vs. biological variability (8 distinct donors run through a single NIST workflow)
  • Sample size: 7 companies × 3 kits ordered (21 kits); one company returned only 2 usable reports after two sample-QC failures. A panel of 8 donors was used for the biological-variability comparison.
  • Duration: Single-timepoint benchmarking; company reports returned ~2–8 weeks after shipment. No longitudinal or repeat-testing component.
  • Funding / conflicts of interest: Conducted by NIST (U.S. government agency). Most consequential disclosure: co-author Jacques Ravel is cofounder of LUCA Biologics, a microbiome biotherapeutics company; all other authors declare no competing interests.
  • Clinical/regulatory readiness: Low. There are currently no regulatory-approved clinical microbiome diagnostic tests in the US and only one CE-IVD sequencing-based test in Europe. These DTC products sit between regulated medical devices and minimally regulated wellness products—a distinction the authors note may not be obvious to consumers.
  • Main limitation: The reference material is not an absolute “ground truth,” so the study measures precision/reproducibility, not accuracy—it cannot determine which company is closest to a sample’s true composition. Scope is also limited to seven companies, with samples shipped under ambient (spring) conditions.

Reference

Servetas, S. L., Gierz, K. S., Hoffmann, D., Ravel, J., & Jackson, S. A. (2026). Evaluating the analytical performance of direct-to-consumer gut microbiome testing services. Communications Biology, 9(1). https://doi.org/10.1038/s42003-025-09301-3


Frequently Asked Questions

How can the same sample come back as both healthy and unhealthy?

Turning stool into a microbiome report involves many steps, from how the sample is collected and shipped to how its DNA is extracted, sequenced and interpreted by software. A small difference at any step can shift the result, and in this study one company’s three identical kits produced two “healthy” verdicts and one “unhealthy” one. The flagged report even passed the company’s own quality checks before being sent.

Does this mean at-home gut tests are a scam?

Not according to the researchers, who say the problem is youth and inconsistency rather than dishonesty. Microbiome science is only about twenty years old, and there isn’t yet an agreed definition of a healthy gut to measure against. The kits can be interesting, but their results aren’t yet reliable enough to act on like a medical diagnosis.

Why does the lack of standards matter for my health?

Many people who buy these tests are dealing with chronic gut issues and hoping for answers. If a result is inaccurate, it could prompt an unnecessary diet change, a costly supplement, or a delay in seeing a doctor who could actually help. That is why the researchers are pushing for shared measurement standards across the industry.

Could these tests ever become as trustworthy as a blood test?

That is exactly the goal. NIST is now working with several of the companies to improve how the measurements are made and reported. If the industry adopts common reference materials and minimum standards, gut tests could one day join routine health screenings rather than sit in a grey zone between wellness gadget and medical tool.

  • Dylan Callaghan

    Journalist & author, 20+ years · Culture, creativity & research

    Dylan Callaghan is a journalist and author based in Los Angeles. For two decades, his work has traced the intersection of culture, creativity, and research; where the sciences and the arts stop being separate conversations. He came to research journalism by way of Hollywood. As a features writer for The Hollywood Reporter, he profiled the people shaping the industry, from Quentin Tarantino to Joel and Ethan Coen. That work led to a long relationship with the Writers Guild of America West, where he wrote for its magazine Written By, and to Script Tease: Today's Hottest Screenwriters Bare All (Simon & Schuster), a collection of candid interviews with writers including Christopher Nolan and Aaron Sorkin on how the work actually gets made. Since 2016 he has covered research, first as a contributing editor at ScienceBlog.com, reporting on everything from Alzheimer's disease to oncology. He brings the same instinct to both beats: find the person doing the work, ask what they were trying to figure out, and explain it well to others.

    On Amazon ↗ · Editorial Policy & Corrections↗

Cite This Page

"Seven Gut Microbiome Tests, One Sample of Poop." ScholarPeer, 24 June 2026, scholarpeer.com/seven-gut-microbiome-tests-one-sample-of-poop/.

Download RIS · Download BibTeX